FDA Bans Certain Imports From Indian Drugmaker Wockhardt
The so-called import alert affects medications that Wockhardt produces at a plant in the Indian city of Aurangabad, which sits about 200 miles east of Mumbai. Company executives predicted it will take months to have the ban lifted and that, in a worst-case scenario, they stand to lose $100 million in revenue, according to published reports.
Wockhardt has 14 manufacturing...
To view the full article, register now.